Clinical Research Directory

Inclusion Criteria: 1. Male or female patients aged ≥18 years; 2. Patients enrolled on the same day as the first prescription with BDP/FF NEXThaler® 100/6 micrograms, or having ongoing treatment with BDP/FF NEXThaler® 100/6 micrograms started within the previous 14 days (maximum), as per local standard clinical practice. 3. Not adequately controlled asthmatic patients (according to clinician's judgement) when BDP/FF NEXThaler® 100/6 micrograms was prescribed; 4. Patients not treated with extrafine formulations during the 6 months before starting the treatment with BDP/FF NEXThaler®; 5. Written informed consent to participate in the study and for the processing of personal data. Exclusion Criteria: 1. Recent (i.e. within the last 6 months) history of life-threatening asthma exacerbations; 2. Diagnosis of chronic obstructive pulmonary disease (COPD); 3. Asthmatic patients on treatment with biologic agents (e.g. monoclonal antibodies) and/or extemporary or fixed triple combinations (e.g. long-acting β2 agonist (LABA)/long-acting muscarinic antagonist (LAMA)/inhaled corticosteroid (ICS) at any dose regimen; 4. Patients with uncontrolled/clinically significant diseases (according to clinician's judgement) or inability to understand and fill in study questionnaires; 5. Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study.